HomeGrants › PAR-26-152

Forecasted

Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional)

Federal funding opportunity PAR-26-152 from National Institutes of Health.

View forecast on Grants.gov →Forecasted — not yet open

Posted
March 3, 2026
Closes
See announcement
Cost sharing
No
Instrument
Grant
Assistance listing
93.395
Category
Health

Program funding history

Awards made under Assistance Listing 93.395 across FY2024–FY2026, from public federal spending records.

FY2024 obligated
$1.1B
FY2025 obligated
$1.3B
FY2026 (to date) obligated
$507.4M
Awards in window
3,932

Top recipients: The Univeristy of Texas M.d. Anderson Cancer Center, Dana-farber Cancer Institute, Inc., Icahn School of Medicine at Mount Sinai, Fred Hutchinson Cancer Center, Sloan-kettering Institute for Cancer Research

Source: USAspending.gov · refreshed July 2026

Synopsis

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits research projects that investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments. Early synthetic lethality–based therapeutic strategies in oncology primarily focused on targeting fixed mutations or genomic abnormalities. More recently, however, it has become clear that clinical benefit is often determined by context-dependent vulnerabilities arising from the intrinsic mutational landscape and adaptive tumor responses.

This NOFO is unique in its scope, supporting innovative cancer therapy strategies that explicitly exploit context-dependent effects of radiation therapy (RT) using drug-radiation combinations. The central premise of the PAIRS is that these conditional RT-induced responses can be leveraged to create or enhance actionable vulnerabilities that synergize with molecularly targeted agents for better outcomes. A defining feature of PAIRS is its emphasis on precision, scientific rigor, and reproducibility, aligned with NIH’s scientific priorities. Radiation effects are clinically titratable through advances in delivery accuracy and flexibility, including dose, schedule, and spatial targeting. These capabilities enable the rational design of conditional RT-synthetic combination strategies that preferentially exploit tumor-specific essentialities while sparing normal tissues, thereby enhancing the therapeutic index by optimizing biological response. This NOFO consolidates the prior exploratory/developmental and research project funding opportunities to streamline the application process and maintain momentum in developing approaches that target actionable vulnerabilities within the defined radiation research scope. The applicants may submit either for exploratory/developmental research projects with a project period of up to 2 years or for research projects with a project period of 4 to 5 years. 

 

Who can apply

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

How to apply

Applications go through the official government listing. Grants Radar links you straight to the source.

View on Grants.gov

Agency contact: NCI PAIRS Program · Email: pairsresearchgrants@nih.gov · Telephone: 240-276-5703

Get grants like this every Tuesday — free

One email a week: the biggest new federal grants and what’s closing soon. Unsubscribe in one click.

The free edition carries one clearly labeled sponsor slot. No spam, ever. Privacy

Similar grants

Never miss a funding deadline again

Grants Radar sends AI-enriched alerts on federal grants and contracts matched to what you do. Founding seats are limited and locked for life.

Get funding alerts